Tildrakizumab (Genetical Recombination)



Tildrakizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human interleukin-23 α subunit (p19) antibody, human framework regions and human IgG1constant regions. Tildrakizumab is produced in Chinese hamster ovary cells. Tildrakizumab is a glycoprotein(molecular weight: ca. 147,000) composed of 2 H-chains (γ1-chains) consisting of 446 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.

[1326244-10-3]